Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature
Objective To assess whether the polymyalgia rheumatica (PMR)-like syndrome reported as an immune related adverse event (irAE) from checkpoint inhibitor therapy is consistent with the 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) provisional criteria for PMR.M...
Saved in:
Main Authors: | Marie Kostine, Laura C Cappelli, Cassandra Calabrese, Elizabeth Kirchner, Tawnie Braaten, Leonard Calabrese |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-06-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/5/1/e000906.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
POLYMYALGIA RHEUMATICA
by: A. M. Satybaldyev, et al.
Published: (2018-05-01) -
The evolution of diagnosis of polymyalgia rheumatica
by: A. M. Satybaldyev
Published: (2019-12-01) -
Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases
by: Alexey D. Meshkov, et al.
Published: (2024-09-01) -
Polymyalgia Rheumatica (PMR) and Polymyalgia Rheumatica-like (PMR-like) Manifestations in Cancer Patients Following Treatment with Nivolumab and Pembrolizumab: Methodological Blurred Points Identified Through a Systematic Review of Published Case Reports
by: Ciro Manzo, et al.
Published: (2025-04-01) -
REVIEW OF RECOMMENDATIONS FOR THE MANAGEMENT OF POLYMYALGIA RHEUMATICA (ACR/EULAR 2015)
by: M. T. Vatutin, et al.
Published: (2016-03-01)